Comparison of the biological principles underlying the action of monoclonal antibody (mAb) and decoy receptor anti-VEGF agents - On the example of ranibizumab (anti-VEGF-A mAb) and aflibercept (decoy VEGFR1-2 receptor);Porównanie zasady biologicznej leża̧cej u podstaw działania czynników skierowanych przeciwko VEGF, opieraja̧cych siȩ na przeciwciałach monoklonalnych (mAb) i receptorach-pułapkach - Na przykładzie ranibizumabu (mAb anty-VEGF-A) i afliberceptu (receptor-pułapka VEGFR1-2)

Klinika Oczna

Volumn 114, Issue 1, 2012, Pages 79-83

  Golik, Paweł ^a   Tońska, Katarzyna ^a  

^a UNIVERSITY OF WARSAW   (Poland)

Author keywords

Aflibercept; AMD; PIGF; Ranibizumab; VEGF

Indexed keywords

AFLIBERCEPT; HYBRID PROTEIN; MONOCLONAL ANTIBODY; RANIBIZUMAB; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

DRUG ANTAGONISM; EYE TUMOR; HUMAN; METABOLISM; RETINA MACULA DEGENERATION; REVIEW; TRANSPORT AT THE CELLULAR LEVEL;

ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL TRANSPORT; EYE NEOPLASMS; HUMANS; MACULAR DEGENERATION; RECOMBINANT FUSION PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR B; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84864569689     PISSN: 00232157     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Carmeliet P, Jain RK: Molecular mechanisms and clinical applications ofangiogenesis. Nature 2011, 473, 298-307.
2. Chiang A, Regillo CD: Preferred therapies for neovascular age-related macular degeneration. Curr Opin Ophthalmol 2011, 22, 199-204.
3. Sharma PS, Sharma R, Tyagi T: VEGF/VEGFR pathway inhibitors as anti-angiogenic agents: present and future. Curr Cancer Drug Targets 2011, 11, 624-653.
4. Ferrara N, Damico L, Shams N, Lowman H, Kim R: Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006, 26, 859-870. (Pubitemid 44547437)
5. Waldmann TA: Immunotherapy: past, present and future. Nat Med 2003, 9, 269-277. (Pubitemid 36362781)
6. Murphy K, Travers P, Walport M, Janeway C: Janeway's Immunobiology. 7th edition. Garland Science 2007.
7. McCafferty J, Griffiths AD, Winter G, Chiswell DJ: Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990, 348, 552-554. (Pubitemid 120015109)
8. Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G: By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol 1991, 222, 581-597.
9. Chaudhary VK, Queen C, Junghans RP, Waldmann TA, Fitzgerald DJ, Pastan I: A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature 1989, 339, 394-397. (Pubitemid 19144230)
10. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G: Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986, 321, 522-525. (Pubitemid 16052256)
11. Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, Duncan JF, Avdalovic NM, Levitt M, Junghans RP, Waldmann TA: A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA 1989, 86, 10029-10033. (Pubitemid 20030769)
12. Tempest PR, Bremner P, Lambert M, Taylor G, Furze JM, Carr FJ, Harris WJ: Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo. Biotechnology (NY) 1991, 9, 266-271.
13. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997, 57, 4593-4599. (Pubitemid 27441066)
14. Los M, Roodhart JM, Voest EE: Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 2007, 12, 443-450. (Pubitemid 46698722)
15. Abouammoh M, Sharma S: Ranibizumab versus bevacizumab for the treatment of neovascular age-related macular degeneration. Curr Opin Ophthalmol 2011, 22, 152-158.
16. Chen Y, Wiesmann C, Fuh G, Li B, Christinger HW, McKay P, De Vos AM, Lowman HB: Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol 1999, 293, 865-881. (Pubitemid 29527672)
17. Mitchell P: A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab. Curr Med Res Opin 2011, 27, 1465-1475.
18. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Joffe E et al.: VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002, 99, 11393-11398. (Pubitemid 34920936)
19. Chu QS: Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors. Expert Opin Biol Ther 2009, 9, 263-271.
20. Teng LS, Jin KT, He KF, Zhang J, Wang HH, Cao J: Clinical applications of VEGF-trap (aflibercept) in cancer treatment. J Chin Med Assoc 2010, 73, 449-456.
21. Jin K, Shen Y, He K, Xu Z, Li G, Teng L: Aflibercept (VEGF Trap): one more double-edged sword of anti-VEGF therapy for cancer? Clin Transl Oncol 2010, 12, 526-532.
22. Saishin Y, Takahashi K, Lima De Silva R, Hylton D, Rudge JS, Wiegand SJ, Campochiaro PA: VEGF-TRAP (R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol 2003, 195, 241-248. (Pubitemid 36384298)
23. Jackson TL, Antcliff RJ, Hillenkamp J, Marshall J: Human retinal molecular weight exclusion limit and estimate of species variation. Invest Ophthalmol Vis Sci 2003, 44, 2141-2146. (Pubitemid 36520310)
24. Roy H, Bhardwaj S, Yla-Herttuala S: Biology of vascular endothelial growth factors. FEBS Lett 2006, 22, 2879-2887. (Pubitemid 43729175)
25. Ribatti D: The controversial role of placental growth factor in tumor growth. Cancer Lett 2011, 307, 1-5.
26. Eriksson A, Cao R, Pawliuk R, Berg SM, Tsang M, Zhou D, Fleet C, Tritsaris K, Dissing S, Leboulch P, Cao Y: Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PIGF-1/VEGF heterodimers. Cancer Cell 2002, 1, 99-108. (Pubitemid 41039180)
27. Lapaire O, Shennan A, Stepan H: The preeclampsia biomarkers soluble fms-like tyrosine kinase-1 and placental growth factor: current knowledge, clinical implications and future application. Eur J Obstet Gynecol Reprod Biol 2010, 151, 122-129.
28. Khurana R, Moons L, Shafi S, Luttun A, Collen D, Martin JF, Carmeliet P, Zachary IC: Placental growth factor promotes atherosclerotic intimal thickening and macrophage accumulation. Circulation 2005, 111, 2828-2836. (Pubitemid 40791556)
29. Van De Veire S, Stalmans I, Heindryckx F, Oura H, Tijeras-Raballand A, Schmidt T, Loges S, Albrecht I, Jonckx B, Vinckier S, Van Steenkiste C et al.: Further pharmacological and genetic evidence for the efficacy of PIGF inhibition in cancer and eye disease. Cell 2010, 141, 178-190.